These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11832981)

  • 21. Rofecoxib and inflammatory bowel disease: clinical and pathologic observations.
    Wilcox GM; Mattia AR
    J Clin Gastroenterol; 2005 Feb; 39(2):142-3. PubMed ID: 15681911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
    MMW Fortschr Med; 2001 Jun; 143(23):34-5. PubMed ID: 11460416
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

  • 25. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
    Morović-Vergles J
    Reumatizam; 2003; 50(2):47-8. PubMed ID: 15098376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib.
    Gornet JM; Hassani Z; Modiglian R; Lémann M
    Am J Gastroenterol; 2002 Dec; 97(12):3209-10. PubMed ID: 12492220
    [No Abstract]   [Full Text] [Related]  

  • 33. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
    Prescrire Int; 2003 Jun; 12(65):89-90. PubMed ID: 12825570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Erosive enteropathy in a patient with polyarthritis].
    Bogas M; Afonso Mdo C; Araújo D
    Acta Reumatol Port; 2006; 31(4):349-54. PubMed ID: 17334047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 36. Psoriasis associated with rofecoxib.
    Clark DW; Coulter DM
    Arch Dermatol; 2003 Sep; 139(9):1223. PubMed ID: 12975177
    [No Abstract]   [Full Text] [Related]  

  • 37. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
    Lamarque D
    Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis.
    Caroli A; Monica F
    Am J Gastroenterol; 2001 May; 96(5):1663-5. PubMed ID: 11374736
    [No Abstract]   [Full Text] [Related]  

  • 40. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.